Logo image of DNMR

DANIMER SCIENTIFIC INC (DNMR) Stock Fundamental Analysis

NYSE:DNMR - New York Stock Exchange, Inc. - US2362721001 - Common Stock - Currency: USD

4.13  -0.59 (-12.5%)

Fundamental Rating

2

Overall DNMR gets a fundamental rating of 2 out of 10. We evaluated DNMR against 85 industry peers in the Chemicals industry. DNMR has a bad profitability rating. Also its financial health evaluation is rather negative. DNMR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DNMR has reported negative net income.
DNMR had a negative operating cash flow in the past year.
DNMR had negative earnings in each of the past 5 years.
DNMR had a negative operating cash flow in each of the past 5 years.
DNMR Yearly Net Income VS EBIT VS OCF VS FCFDNMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -17.27%, DNMR is not doing good in the industry: 88.10% of the companies in the same industry are doing better.
DNMR has a worse Return On Equity (-52.55%) than 86.90% of its industry peers.
Industry RankSector Rank
ROA -17.27%
ROE -52.55%
ROIC N/A
ROA(3y)-18.22%
ROA(5y)-11.26%
ROE(3y)-38.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DNMR Yearly ROA, ROE, ROICDNMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DNMR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNMR Yearly Profit, Operating, Gross MarginsDNMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

DNMR does not have a ROIC to compare to the WACC, probably because it is not profitable.
DNMR has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, DNMR has a worse debt to assets ratio.
DNMR Yearly Shares OutstandingDNMR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
DNMR Yearly Total Debt VS Total AssetsDNMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -1.42, we must say that DNMR is in the distress zone and has some risk of bankruptcy.
DNMR has a Altman-Z score of -1.42. This is amonst the worse of the industry: DNMR underperforms 85.71% of its industry peers.
DNMR has a Debt/Equity ratio of 1.80. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.80, DNMR is not doing good in the industry: 84.52% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF N/A
Altman-Z -1.42
ROIC/WACCN/A
WACC5.84%
DNMR Yearly LT Debt VS Equity VS FCFDNMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 3.28 indicates that DNMR has no problem at all paying its short term obligations.
DNMR has a better Current ratio (3.28) than 86.90% of its industry peers.
DNMR has a Quick Ratio of 2.05. This indicates that DNMR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.05, DNMR is in the better half of the industry, outperforming 77.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.28
Quick Ratio 2.05
DNMR Yearly Current Assets VS Current LiabilitesDNMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for DNMR have decreased strongly by -825.53% in the last year.
Looking at the last year, DNMR shows a very negative growth in Revenue. The Revenue has decreased by -26.71% in the last year.
The Revenue has been decreasing by -0.46% on average over the past years.
EPS 1Y (TTM)-825.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1130.77%
Revenue 1Y (TTM)-26.71%
Revenue growth 3Y-0.46%
Revenue growth 5YN/A
Sales Q2Q%-21.17%

3.2 Future

Based on estimates for the next years, DNMR will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.49% on average per year.
DNMR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 52.38% yearly.
EPS Next Y-2009.57%
EPS Next 2Y-258.17%
EPS Next 3Y-108.23%
EPS Next 5Y18.49%
Revenue Next Year-18.56%
Revenue Next 2Y31.78%
Revenue Next 3Y53.32%
Revenue Next 5Y52.38%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DNMR Yearly Revenue VS EstimatesDNMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
DNMR Yearly EPS VS EstimatesDNMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DNMR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DNMR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNMR Price Earnings VS Forward Price EarningsDNMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNMR Per share dataDNMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60

4.3 Compensation for Growth

A cheap valuation may be justified as DNMR's earnings are expected to decrease with -108.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-258.17%
EPS Next 3Y-108.23%

More info and screens

0

5. Dividend

5.1 Amount

DNMR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DANIMER SCIENTIFIC INC

NYSE:DNMR (12/30/2024, 8:08:00 PM)

4.13

-0.59 (-12.5%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)11-19 2024-11-19/bmo
Earnings (Next)N/A N/A
Inst Owners31.85%
Inst Owner Change0%
Ins Owners9.26%
Ins Owner Change0%
Market Cap12.47M
Analysts45
Price Target4.76 (15.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.58%
Min EPS beat(2)19.01%
Max EPS beat(2)42.14%
EPS beat(4)4
Avg EPS beat(4)15.98%
Min EPS beat(4)0.17%
Max EPS beat(4)42.14%
EPS beat(8)6
Avg EPS beat(8)7.58%
EPS beat(12)6
Avg EPS beat(12)-34.15%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-10.33%
Min Revenue beat(2)-19.32%
Max Revenue beat(2)-1.34%
Revenue beat(4)0
Avg Revenue beat(4)-8.85%
Min Revenue beat(4)-19.32%
Max Revenue beat(4)-1.34%
Revenue beat(8)0
Avg Revenue beat(8)-12.4%
Revenue beat(12)0
Avg Revenue beat(12)-14.21%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15.15%
PT rev (3m)449.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3326.05%
EPS NY rev (1m)1.92%
EPS NY rev (3m)-3781.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-53.05%
Revenue NY rev (1m)3.66%
Revenue NY rev (3m)0.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB 0.09
EV/EBITDA N/A
EPS(TTM)-13.05
EYN/A
EPS(NY)-19.5
Fwd EYN/A
FCF(TTM)-23.79
FCFYN/A
OCF(TTM)-20.66
OCFYN/A
SpS12.39
BVpS70.06
TBVpS44.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.27%
ROE -52.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.22%
ROA(5y)-11.26%
ROE(3y)-38.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.81%
Cap/Sales 25.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.28
Quick Ratio 2.05
Altman-Z -1.42
F-Score2
WACC5.84%
ROIC/WACCN/A
Cap/Depr(3y)829.12%
Cap/Depr(5y)N/A
Cap/Sales(3y)227.99%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-825.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1130.77%
EPS Next Y-2009.57%
EPS Next 2Y-258.17%
EPS Next 3Y-108.23%
EPS Next 5Y18.49%
Revenue 1Y (TTM)-26.71%
Revenue growth 3Y-0.46%
Revenue growth 5YN/A
Sales Q2Q%-21.17%
Revenue Next Year-18.56%
Revenue Next 2Y31.78%
Revenue Next 3Y53.32%
Revenue Next 5Y52.38%
EBIT growth 1Y29.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year71.81%
EBIT Next 3Y27.74%
EBIT Next 5Y24.28%
FCF growth 1Y75.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.65%
OCF growth 3YN/A
OCF growth 5YN/A